Clinical trial · Observational
Image-derived Prediction of Response to Chemo-radiation in Glioblastoma
Image-derived Prediction of Response to Chemo-radiation in Patients With Glioblastoma
NCT02329795CI-TRIAL-00029892IDEPREGterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Slow accrual
Summary
Brief summary (as posted)
This study seeks to investigate if advanced image-analysis of diagnostic scans, can be used to predict how aggressive brain tumors (glioblastoma) respond to standard chemo- and radiation treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
| Temozolomide | Drug | Temozolomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Standard chemoradiotherapy
- description
- Group to receive 60 Gy radiotherapy in 30 fractions with concomitant and adjuvant temozolomide.
- interventionNames
- Radiation: Radiotherapy
- Drug: Temozolomide
Primary outcomes (1)
- measure
- Sensitivity and specificity of predicted response
- timeFrame
- 3 months post radiotherapy
- description
- Tumor response is measured as contrast-enhancing tumor on T1-weighted MRI and by metabolic active tumor using 18F-fluroethyl-tyrosine (FET)-PET. Pre-treatment risk map is constructed using machine learning methods and compared to post-treatment scans.
Secondary outcomes (2)
- measure
- DICE-similarity coefficient and percentage overlap of 64Cu-ATSM and contrast-enhanced T1-weighted MRI
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed, primary supratentorial glioblastoma (WHO grade IV). Exclusion Criteria: * No informed consent can be obtained * Inability to undergo MRI examination, due to metal implants, pacemaker etc. * Not eligible for Stupp-regimen
References
Publications (0)
Data not yet available
No reference posted for this study.